Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Prof. Dr. Stefan M. Gold | UNKNOWN |
| Prof. Dr. Soyoung Q Park | UNKNOWN |
| Dr. Ulrike Grittner | UNKNOWN |
| Motognosis GmbH |
Not provided
Not provided
Not provided
Not provided
A large body of evidence on depression heterogeneity point to an "immunometabolic" subtype characterized by the clustering of immunometabolic dysregulations with atypical behavioral symptoms related to energy homeostasis. Motivational and motor impairments reflected by symptoms of anhedonia and psychomotor retardation in major depression are closely related to alterations in energy homeostasis, are associated with increased inflammation, and may be a direct consequence of the impact of inflammatory cytokines on the dopamine system in the brain. In the proposed project, the investigators will examine the effect of dopamine stimulation on motivation and motor function in patients with major depression and healthy controls and the role of inflammation using a double-blind, randomized, placebo-controlled, cross-over design. If successful, this study would provide crucial evidence that pharmacologic strategies that increase dopamine may effectively treat inflammation-related symptoms of anhedonia and psychomotor retardation in major depression.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| L-dopa/Carbidopa followed by placebo | Experimental | Participants will receive first L-dopa/Carbidopa (100/25 mg), and then placebo. |
|
| Placebo followed by L-dopa/Carbidopa | Experimental | Participants will receive first placebo, and then L-dopa/Carbidopa (100/25 mg). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| L-dopa/Carbidopa | Drug | Patients and healthy controls will receive one time administration of L-dopa/Carbidopa (100/25 mg). |
|
| Measure | Description | Time Frame |
|---|---|---|
| The change in response bias (logb) after L-dopa/Carbidopa compared to placebo in the Probabilistic Reward Task (PRT). | The PRT, which uses a signal detection paradigm, will be used to measure response bias, the propensity to select the more rewarded response ("rich"). | All participants will be tested on two separate experimental sessions separated by an interval of 48 hours, after L-dopa/Carbidopa or placebo. |
| The change in mean gait speed [m/s] after L-dopa/Carbidopa compared to placebo in the dual task. | The dual task mean gait speed will be measured with six wearable inertial measurement units. In this dual task, participants walk at their usual speed while naming as many animals as possible. | All participants will be tested on two separate experimental sessions separated by an interval of 48 hours, after L-dopa/Carbidopa or placebo. |
| Measure | Description | Time Frame |
|---|---|---|
| The change in choice of the hard task after L-dopa/Carbidopa compared to placebo in the Effort Expenditure for Rewards Task (EEfRT). | The EEfRT, a widely used, multi-trial task in which participants are given an opportunity on each trial to choose between two different task difficulty levels in order to obtain monetary rewards, will be used as an objective measure of reward motivation. The EEfRT is reported as the percent of high effort (hard) trials selected. A higher percentage reflects higher motivation for effort expenditure. |
| Measure | Description | Time Frame |
|---|---|---|
| The change in speed and accuracy after L-dopa/Carbidopa compared to placebo in the Rapid Visual Information Processing Task (RVP). | The RVP from the Cambridge Neuropsychological Test Automated Battery (CANTAB) will be used to assess performance speed (mean latency for correct responses) and accuracy (target sensitivity score). | All participants will be tested on two separate experimental sessions separated by an interval of 48 hours, after L-dopa/Carbidopa or placebo. |
Inclusion Criteria:
For patients with major depressive disorder:
For healthy participants:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Woo Ri Chae, MD MSc | Contact | +49 30 450 517625 | woo-ri.chae@charite.de |
| Name | Affiliation | Role |
|---|---|---|
| Woo Ri Chae, MD MSc | Charite University, Berlin, Germany | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Klinik für Psychiatrie und Psychotherapie | Recruiting | Steglitz | 12203 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| D003863 | Depression |
| D007249 | Inflammation |
| D059445 | Anhedonia |
| D011596 | Psychomotor Disorders |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
| D001526 | Behavioral Symptoms |
Not provided
Not provided
| UNKNOWN |
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Patients and healthy controls will receive one time administration of Placebo. |
|
| All participants will be tested on two separate experimental sessions separated by an interval of 48 hours, after L-dopa/Carbidopa or placebo. |
| The change in movement time [ms] after L-dopa/Carbidopa compared to placebo in the Reaction Time Task (RTI). | The RTI from the Cambridge Neuropsychological Test Automated Battery (CANTAB) will be used to assess movement time, which is the time taken to touch the stimulus on the computer screen after the press pad had been released. | All participants will be tested on two separate experimental sessions separated by an interval of 48 hours, after L-dopa/Carbidopa or placebo. |
| The change in risk propensity after L-dopa/Carbidopa compared to placebo in the Risky Decision-Making Task. | In the Risky Decision-Making Task, participants have to make choices between a risky option and a safe alternative. Risk Propensity, the proportion of risk-taking trials, will be a secondary outcome. | All participants will be tested on two separate experimental sessions separated by an interval of 48 hours, after L-dopa/Carbidopa or placebo. |
| Response bias (logb) in the PRT | After administration of placebo on Day 2 or Day 3. |
| Mean gait speed [m/s] in the dual task | After administration of placebo on Day 2 or Day 3. |
| Choice of the hard task in the EEfRT | After administration of placebo on Day 2 or Day 3. |
| Movement time [ms] in the RTI | After administration of placebo on Day 2 or Day 3. |
| Risk propensity in the Risky Decision-Making Task | At baseline on Day 1. |
| D001519 |
| Behavior |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |